CH655007A5 - Composition pharmaceutique antihypertensive synergetique. - Google Patents
Composition pharmaceutique antihypertensive synergetique. Download PDFInfo
- Publication number
- CH655007A5 CH655007A5 CH3786/83A CH378683A CH655007A5 CH 655007 A5 CH655007 A5 CH 655007A5 CH 3786/83 A CH3786/83 A CH 3786/83A CH 378683 A CH378683 A CH 378683A CH 655007 A5 CH655007 A5 CH 655007A5
- Authority
- CH
- Switzerland
- Prior art keywords
- pharmaceutical composition
- indapamide
- hydroxypropoxy
- tert
- butylamino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000003276 anti-hypertensive effect Effects 0.000 title description 2
- 230000002195 synergetic effect Effects 0.000 title description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 17
- 229960004569 indapamide Drugs 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 2
- -1 hydroxypropoxy Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 description 11
- 102000030621 adenylate cyclase Human genes 0.000 description 8
- 108060000200 adenylate cyclase Proteins 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
- 229940095074 cyclic amp Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 241000272201 Columbiformes Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8212058A FR2529785A1 (fr) | 1982-07-09 | 1982-07-09 | Composition pharmaceutique a base d'indapamide et de 8-(3-tertbutylamino 2-hydroxypropoxy)-thiachromanne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH655007A5 true CH655007A5 (fr) | 1986-03-27 |
Family
ID=9275835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3786/83A CH655007A5 (fr) | 1982-07-09 | 1983-07-08 | Composition pharmaceutique antihypertensive synergetique. |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5927813A (OSRAM) |
| AU (1) | AU557601B2 (OSRAM) |
| BE (1) | BE897251A (OSRAM) |
| CA (1) | CA1197191A (OSRAM) |
| CH (1) | CH655007A5 (OSRAM) |
| DE (1) | DE3324785C2 (OSRAM) |
| FR (1) | FR2529785A1 (OSRAM) |
| GB (1) | GB2123293B (OSRAM) |
| IE (1) | IE55364B1 (OSRAM) |
| IT (1) | IT1173729B (OSRAM) |
| LU (1) | LU84902A1 (OSRAM) |
| NL (1) | NL8302435A (OSRAM) |
| NZ (1) | NZ204849A (OSRAM) |
| OA (1) | OA07489A (OSRAM) |
| SE (1) | SE8303886L (OSRAM) |
| ZA (1) | ZA834978B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8600137A (nl) * | 1985-02-05 | 1986-09-01 | Sandoz Ag | Farmaceutische preparaten die desgewenst met een diureticum gecombineerde 3-aminopropoxyindolen bevatten, alsmede werkwijzen voor het toepassen van deze preparaten. |
| PL193976B1 (pl) * | 2002-07-01 | 2007-04-30 | Pliva Krakow | Tabletka o przedłużonym działaniu zawierająca indapamid i sposób wytwarzania tabletki o przedłużonym działaniu zawierającej indapamid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203691A (en) * | 1968-03-06 | 1970-09-03 | Science Union & Cie | New disubstituted n-amino indoline derivatives and process for preparing them |
| GB1308191A (en) * | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| DE2227423A1 (de) * | 1971-06-15 | 1972-12-21 | Ciba-Geigy Ag, Basel (Schweiz) | Neue pharmazeutische Präparate |
-
1982
- 1982-07-09 FR FR8212058A patent/FR2529785A1/fr active Granted
-
1983
- 1983-07-06 LU LU84902A patent/LU84902A1/fr unknown
- 1983-07-07 SE SE8303886A patent/SE8303886L/xx not_active Application Discontinuation
- 1983-07-07 IT IT48641/83A patent/IT1173729B/it active
- 1983-07-07 ZA ZA834978A patent/ZA834978B/xx unknown
- 1983-07-08 GB GB08318512A patent/GB2123293B/en not_active Expired
- 1983-07-08 JP JP58124582A patent/JPS5927813A/ja active Granted
- 1983-07-08 DE DE3324785A patent/DE3324785C2/de not_active Expired
- 1983-07-08 CH CH3786/83A patent/CH655007A5/fr not_active IP Right Cessation
- 1983-07-08 NL NL8302435A patent/NL8302435A/nl not_active Application Discontinuation
- 1983-07-08 CA CA000432068A patent/CA1197191A/fr not_active Expired
- 1983-07-08 NZ NZ204849A patent/NZ204849A/en unknown
- 1983-07-08 AU AU16702/83A patent/AU557601B2/en not_active Ceased
- 1983-07-08 OA OA58056A patent/OA07489A/xx unknown
- 1983-07-08 BE BE0/211143A patent/BE897251A/fr not_active IP Right Cessation
- 1983-07-08 IE IE1597/83A patent/IE55364B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE897251A (fr) | 1984-01-09 |
| IE831597L (en) | 1984-01-09 |
| FR2529785A1 (fr) | 1984-01-13 |
| AU557601B2 (en) | 1986-12-24 |
| SE8303886D0 (sv) | 1983-07-07 |
| JPS5927813A (ja) | 1984-02-14 |
| DE3324785C2 (de) | 1986-10-09 |
| ZA834978B (en) | 1984-03-28 |
| FR2529785B1 (OSRAM) | 1984-12-07 |
| LU84902A1 (fr) | 1984-03-22 |
| IE55364B1 (en) | 1990-08-29 |
| CA1197191A (fr) | 1985-11-26 |
| NZ204849A (en) | 1986-04-11 |
| DE3324785A1 (de) | 1984-01-12 |
| SE8303886L (sv) | 1984-01-10 |
| JPH0250084B2 (OSRAM) | 1990-11-01 |
| OA07489A (fr) | 1985-03-31 |
| NL8302435A (nl) | 1984-02-01 |
| GB2123293A (en) | 1984-02-01 |
| AU1670283A (en) | 1984-01-12 |
| GB2123293B (en) | 1985-10-09 |
| IT8348641A0 (it) | 1983-07-07 |
| IT1173729B (it) | 1987-06-24 |
| GB8318512D0 (en) | 1983-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5985868A (en) | Methods and compositions for treating androgen-dependant diseases using optically pure R-(-) casodex | |
| EP1108424B1 (fr) | Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale | |
| AU2004293008A1 (en) | Combination drug therapy to treat obesity | |
| EP1195166B1 (en) | Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension | |
| RU2125448C1 (ru) | Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов | |
| US4469690A (en) | Synergistic compositions of renal dopaminergic agent and β-blocker | |
| CH655007A5 (fr) | Composition pharmaceutique antihypertensive synergetique. | |
| EP0521057A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS. | |
| CA1238576A (en) | Synergistic pharmaceutical composition | |
| Endresen et al. | Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients | |
| Deray et al. | Effects of ciclosporin on plasma renin activity, catecholamines and prostaglandins in patients with idiopathic uveitis | |
| De Smet | Yohimbe Alkaloids–general discussion | |
| Snider et al. | Is dopamine a neurohormone of the adrenal medulla? Studies with morphine stimulation | |
| JP2021535216A (ja) | セバコイルジナルブフィンとアセトアミノフェンの医薬品製剤及び疼痛を治療する方法 | |
| EP2026796B1 (fr) | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire | |
| Strolin Benedetti et al. | Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man | |
| YOKOYAMA et al. | Effects of RS-2232, a potential antidepressant, on the levels of monoamines, precursor amino acids and their related metabolites in mouse brain | |
| LU87777A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
| Rahmani | Vascular smooth muscle, endothelial regulation and effects of aspirin in hypertension | |
| Pendleton | The discovery of potent inhibitors of phenylethanolamine N-methyltransferase (PNMT) | |
| AU779929B2 (en) | Treatment of pulmonary hypertension | |
| Sandberg et al. | The Appearance Of PF1 And PF3 In Activated Human Platelets | |
| Walker et al. | Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-b-hydroxylase | |
| BE825194A (fr) | Hydrazide de n-benzene-sulfonyl-beta-alanine comme agent immunosupressif sur et actif | |
| AU4743699A (en) | Treating conditions using optically pure (-)-liazrozle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |